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Background: An n-6 essential fatty acid, arachidonic acid (ARA) is converted into prostaglandin E2, which is
involved in tumour extension. However, it is unclear whether dietary ARA intake leads to cancer in humans.
We thus systematically evaluated available observational studies on the relationship between ARA exposure and
the risk of colorectal, skin, breast, prostate, lung, and stomach cancers.
Methods: We searched the PubMed database for articles published up to May 17, 2010. 126 potentially relevant
articles from the initial search and 49,670 bibliographies were scrutinised to identify eligible publications by using
predefined inclusion criteria. A comprehensive literature search yielded 52 eligible articles, and their reporting
quality and methodological quality was assessed. Information on the strength of the association between ARA
exposure and cancer risk, the dose-response relationship, and methodological limitations was collected and
evaluated with respect to consistency and study design.
Results: For colorectal, skin, breast, and prostate cancer, 17, 3, 18, and 16 studies, respectively, were identified.
We could not obtain eligible reports for lung and stomach cancer. Studies used cohort (n = 4), nested case-control
(n = 12), case-control (n = 26), and cross-sectional (n = 12) designs. The number of subjects (n = 15 - 88,795), ARA
exposure assessment method (dietary intake or biomarker), cancer diagnosis and patient recruitment procedure
(histological diagnosis, cancer registries, or self-reported information) varied among studies. The relationship
between ARA exposure and colorectal cancer was inconsistent based on ARA exposure assessment methodology
(dietary intake or biomarker). Conversely, there was no strong positive association or dose-response relationship for
breast or prostate cancer. There were limited numbers of studies on skin cancer to draw any conclusions from the
results.
Conclusions: The available epidemiologic evidence is weak because of the limited number of studies and their
methodological limitations, but nonetheless, the results suggest that ARA exposure is not associated with increased
breast and prostate cancer risk. Further evidence from well-designed observational studies is required to confirm or
refute the association between ARA exposure and risk of cancer.Background
Cancer remains an important health problem worldwide.
It is estimated that 58.8 million people died of all causes
in 2004 [1]. Deaths from cancer represented around
one-eighth of these deaths, although many people who
died had cancer even though it was not the direct cause
of death. By 2030, it is projected that there will be* Correspondence: Mai_Sakai@suntory.co.jp
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reproduction in any medium, provided the orapproximately 26 million new cancer cases and 17 mil-
lion cancer deaths per year [2]. Given these considera-
tions, the prevention of cancer is a major public health
issue around the world.
It is well established that dietary and other lifestyle fac-
tors play an important role in cancer control. In terms
of dietary factors, earlier studies suggested a relationship
between fat intake and the risk of several types of can-
cer. Prospective cohort studies found no association be-
tween fat intake and breast cancer, but a randomised
trial organised within the Women’s Health Initiative trial
suggested a 9% reduction of borderline significance ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Analysis of the information in the Multiethnic Cohort
Study found that intake of different types of fat indicated
no association with overall prostate cancer risk or with
non-localised or high-grade prostate cancer [6]. A pro-
spective cohort study and a clinical trial failed to find evi-
dence for an association between fat intake and colorectal
cancer [7,8]. A dietary intervention study demonstrated
that a reduction in fat intake reduces the risk of skin can-
cer [9,10], but the evidence from observational studies
[11,12] has been controversial. Japan is a high-risk area
for stomach and lung cancer, but no association with fat
intake and these types of cancer has been suggested [2].
Essential fatty acids, namely n-3 and n-6 fatty acids,
are involved in many important biological functions
[13-16]. They play a structural role in cell membranes,
influencing their fluidity and membrane enzyme activ-
ities; in addition, some are the precursors of prostaglan-
dins and other lipid mediators. Arachidonic acid (ARA)
is an n-6 essential fatty acid and also a major constituent
of biomembranes. It is released from membranes by
phospholipase A2 and converted into various lipid med-
iators that exert many physiological actions [17-19].
Many studies have shown that lipid mediators derived
from ARA, particularly prostaglandin E2 (PGE2), are
associated with various diseases, which is mainly based
on the fact that cyclooxygenase (COX) inhibitors are ef-
fective against those conditions [20-24]. PGE2 is regarded
as enhancing tumour extension as well, but it has been
suggested that some other ARA mediators inhibit
tumour growth [21-25]. In animal models, ARA adminis-
tration did not affect tumour extension [26,27]. Some ob-
servational studies also suggested no relationship
between ARA exposure and cancer risk [28,29]. However,
there are the inconsistent observational studies that ARA
exposure was positively correlated with the risk of colorec-
tal cancer [30,31]. ARA is one of the major polyunsatur-
ated fatty acid, and this inconsistency is not negligible.
No systematic review or meta-analysis has been con-
ducted to evaluate the long-term effects of ARA intake
and blood or tissue ARA composition on the risk of
colorectal, skin, breast, prostate, lung, and stomach can-
cers in free-living populations. The objective of this
study was to systematically evaluate available observa-
tional studies on the relationship between ARA intake
and blood or tissue composition of ARA and the risk of
these types of cancer.
Methods
Search strategy
The PubMed database (http://www.ncbi.nlm.nih.gov/
pubmed/) was searched for observational studies on the
relationship between dietary or blood ARA levels with
cancer risk that were published up to May 17, 2010. Toidentify target articles effectively, the strategy for the
PubMed search was as follows: keywords for outcome
and study types were adopted as commonly used terms
representing cancer and study design, whereas terms for
exposure were selected from specific words that stand
for “arachidonic acid” (see Additional file 1). The initial
PubMed search yielded 126 potentially relevant articles.
Study selection
Inclusion criteria were English articles that reported ori-
ginal data on the relationship between ARA exposure
(intake or blood level) and target cancer risk in free-
living adults. Eligible study designs were cohort, case-
control, or cross-sectional studies, and target types of
cancer were colorectal, skin, breast, prostate, lung, or
stomach cancer. Also included were studies investigating
tissue ARA levels and target cancer risk. The study se-
lection process is presented in Figure 1. We omitted
reports in which titles or abstracts indicated that: (1)
they were not human studies; (2) they were limited to
special populations such as people with unusual eating
habits; (3) they were intervention studies; or (4) they
were not about the target cancers and fatty acids (not
fat). We then evaluated the full text of the passed arti-
cles. Titles and abstracts of 126 identified publications
from the PubMed database were checked and reviewed
against the predefined inclusion criteria, and afterward,
the full text of 52 articles were similarly assessed for eligi-
bility by three authors (SK, CH, and HT, not independ-
ently). The 49,670 bibliographies of these full-text articles
were scrutinised to identify additional eligible publica-
tions. One article on breast cancer was excluded because
an inaccuracy of ARA assessment was clearly reported, al-
though this article met the inclusion criteria described
above [32]. Finally, 52 eligible articles were included in
this review: 21 and 31 articles were obtained from pri-
mary PubMed searches and bibliographies, respectively.
Quality assessment and data extraction
Quality assessment was conducted based on the report-
ing quality and methodological quality of each study.
The reporting quality shows whether the necessary in-
formation for observational studies is well indicated. It is
the number of fulfilled items from the Strengthening the
Reporting of Observational Studies in Epidemiology
Statement (STROBE) checklist and varied 0 to 34 [33].
The reporting quality of included observational studies
was assessed individually by two reviewers (CH and HT)
and then confirmed by another two authors (SK and
MS). The methodological quality, a level of suitability
of methods used in a study, was assessed by two
authors (SK and MS) qualitatively from the following
methodological aspects used in the article: subject selec-
tion, ARA exposure assessment, diagnosis or recruitment
126 potentially relevant 
articles identified from 
PubMed database
52 articles included in this 
review
74 articles excluded for 
not meeting review 
criteria 
790 full-text articles for 
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47,971 articles 
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52 full-text articles for 
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759 articles excluded 



























Figure 1 Flow diagram for literature search and study selection. CH Cohort study, NCC Nested case-control study, CC Case-control study, CS
Cross-sectional study. *One article that includes data on colorectal, breast and prostate cancer is counted as three studies.
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confounders, and statistical analysis.
For each eligible article, the following information was
tabulated: authors and year of publication, study settings
and design, subject characteristics (such as age, sex,
and number), matching strategy (if applicable), ARA
exposure assessment used (as well as information about
validity or precision), outcome assessment, adjusted con-
founders, reporting quality score from the STROBE
checklist, and main findings from the fully adjusted
model. Case-control studies were classified into two
groups based on whether they reported temporal study
settings information between exposure and outcome as-
sessment: “case-control study (temporal relationship
among exposure and outcome is demonstrated)” was
defined as articles in which ARA exposure preceded the
occurrence of cancer, whereas “case-control study (tem-
poral relationship among exposure and outcome is un-
clear)” did not describe sufficient temporal information
about exposure and outcome assessment.
Our qualitative definition of the study quality was as
below: the reporting quality score under 13 or theinsufficient temporal information, low; the other studies
were qualitatively divided into high/medium/low accord-
ing to their strength and weakness. A meta-analysis was
not conducted because of the heterogeneity among stud-
ies, particularly subject characteristics and exposure/out-
come assessment, and the insufficient number of studies
with high methodological quality suitable for a meta-
analysis. Therefore, qualitative assessment of ARA intake
and cancer risk is presented in this review.
Results
For colorectal, skin, breast, and prostate cancer, 52 eli-
gible articles were selected from potentially related
reports and were included in the present systematic re-
view (Figure 1); the number of each was 17, 3, 18, and
16 studies, respectively. In contrast, we could not iden-
tify eligible reports for lung and stomach cancer.
Colorectal cancer
Major characteristics are shown in Table 1 [28,30,31,34-47].
Five reports did not provide sufficient information about
the methodology of outcome measurement. Some cohort
Table 1 Summary of observational studies on the association between ARA and risk of colorectal cancer
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Q1: 0.02 1.00 0.03
Q2: 0.03 1.20 (0.87-1.64)
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Q1: 0.04 1.00 0.55
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Study design: nested case-control study
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Q4: ≥5.635 0.65 (0.30-1.44)
Study design: case-control study (temporal relationship among exposure and outcome is demonstrated)
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Table 1 Summary of observational studies on the association between ARA and risk of colorectal cancer (Continued)
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Table 1 Summary of observational studies on the association between ARA and risk of colorectal cancer (Continued)
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Study design: cross-sectional study
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Table 1 Summary of observational studies on the association between ARA and risk of colorectal cancer (Continued)
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24-HDR 24-h dietary recall, ARA Arachidonic acid, BMI Body mass index, CRA Colorectal adenoma, CRC Colorectal cancer, DM Diabetes mellitus, FAP Familial adenomatous polyposis, FFQ Food frequency questionnaire,
GC Gas chromatography, HNPCC Hereditary non-polyposis colorectal cancer, HRT Hormone replacement therapy, JACC Japan Collaborative Cohort, NMSC Nonmelanoma skin cancer, NSAIDs Nonsteroidal
antiinflammatory drugs, OR Odds ratio, PHS Physician's health study, RR Relative risk, SWHS Shanghai Women's Health Study, UK United Kingdom, USA United States of America, WHS Women's Health Study, WR
Weighed dietary record.
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potential confounders, such as family history, body
weight and smoking, and specific factors for colorectal
cancer, such as body mass index (BMI), physical activity,
alcohol drinking and total energy. No confounding fac-
tors were adjusted for in eight articles.
Dietary ARA intake was estimated in two cohort stud-
ies and four case-control studies. Median dietary ARA
intake ranged widely from 0.008 to 0.15 g/day, or from
0.04% to 0.07% of energy. Two articles reported a signifi-
cant increase in colorectal cancer risk. Muff et al. indi-
cated that colorectal cancer risk was significantly
increased in the third and fourth quintiles of ARA in-
take, and that the overall trend was significant (P for
trend = 0.03). Nkondjock et al. reported significantly
increased colorectal cancer risk in the third and fourth
quartiles and significance in the overall trend (P for
trend = 0.001).
In seven case-control studies and three cross-sectional
studies, the exposure was indicated as blood ARA levels.
The precision of blood analysis was mentioned in only
four reports, and blinded fatty acid measurement was
conducted in only three reports. Five articles showed a
significant trend of decreasing colorectal cancer risk or a
significant difference of blood ARA levels in cancer sub-
jects. Kuriki et al. found that colorectal cancer risk was
significantly decreased in the highest tertile of erythro-
cyte ARA levels, and that the overall trend was signifi-
cant (P for trend < 0.05). The remaining four reports,
Ghadimi et al., Hietanen et al., Neoptolemos et al.
(1988), and Almending et al., were a case-control study
with little temporal information between exposure and
outcome or a cross-sectional study.
One case-control study with little temporal informa-
tion between exposure and outcome and two cross-
sectional studies investigated tissue ARA levels. The
precision of tissue analysis was mentioned in only one
article, and none reported masking of disease status.
Their reporting quality was generally low.
Skin cancer
Only three articles were included in the present system-
atic review. Major characteristics are shown in Table 2
[48-50]. Their exposure assessment and subjects’ charac-
teristics were too diverse to be compared to each other.
Breast cancer
Major characteristics are shown in Table 3 [29,46,51-66].
Five articles did not provide sufficient information about
the methodology of outcome measurement. In addition to
general confounding factors, specific factors for breast
cancer, such as reproductive factors and history of benign
breast disease, were considered in some articles; however,
no confounding factors were investigated in eight articles.Dietary ARA intake was estimated in one cohort study
and three case-control studies. These four showed no sig-
nificant change in breast cancer risk except in the second
quartile of ARA intake in the report by Nkondjock et al.
Six case-control studies and three cross-sectional stud-
ies investigated blood ARA levels. The precision of
blood analysis was reported in only five articles, and
blinded fatty acid measurement was conducted in only
two articles. Three articles indicated significant differ-
ences in breast cancer risk; however, they were a case-
control study with little temporal information between
exposure and outcome or a cross-sectional study. Aro
et al. reported significantly increased breast cancer risk
in the highest quintile of serum ARA in post-menopausal
women. The reporting quality of the remaining two
articles, those by Zaridze et al. and Williams et al.,
was quite low.
Five case-control studies and two cross-sectional stud-
ies examined tissue ARA levels. The precision of tissue
analysis was mentioned in only three articles, and only
in one report fatty acids measurement was performed in
a blinded fashion. A significant change in breast cancer
risk or a significant difference in tissue ARA level was
not found, except for breast tissue triglyceride ARA
levels in a report by Zhu et al. and breast tissue phos-
phatidylcholine ARA levels in a report by Williams et al.
Prostate cancer
Major characteristics are shown in Table 4 [46,67-81].
Four articles did not provide sufficient information about
the methodology of outcome measurement. As well as
well-known confounding factors, specific factors for pros-
tate cancer, for instance BMI, physical activity, and total
energy, were considered in some articles; however, no
confounding factors were adjusted for in seven articles.
One cohort study and three case-control studies
examined dietary ARA intake. They showed no signifi-
cant change in prostate cancer risk according to
increased ARA intake.
Blood ARA levels were estimated in nine case-control
studies and three cross-sectional studies. The precision
of blood analysis was mentioned in only five articles,
and masking of disease status was conducted in only
four. Ukori et al. (2010) reported that prostate cancer
risk of African-Americans decreased in the fourth quar-
tile of blood ARA level, and that the overall trend was
significant (P for trend < 0.05). A significant change in
prostate cancer risk or a significant difference in blood
ARA levels was not found in the other 11 articles.
Three cross-sectional studies examined tissue ARA
levels. All of them reported significant decreases of tissue
ARA levels in cancer subjects; however, their reporting
quality was generally quite low. None of them mentioned
the precision of tissue analysis and masking of groups.
Table 2 Summary of observational studies on the association between ARA and risk of skin cancer
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24-HDR: 24-h dietary recall, ARA Arachidonic, GC Gas chromatography, OR Odds Ratio, SCC Squamous cell caricinoma, USA United States of America.
*Result of the critical evaluation carried out using the STROBE tool.
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In the present review, we systematically reviewed obser-
vational studies investigating the association between
ARA and cancer of six organs in free-living populations.
Fifty-two eligible articles were obtained from our search
strategy, and 31 out of the 52 articles were identified
from hand searches for references (Figure 1). Thus,
reference searching serves an important role in compre-
hensive literature searches. This pointed out the charac-
teristics of the reporting style of the observational
studies for ARA and cancer risk.
Among the 31 eligible articles from reference searches,
22 were not recognised by our PubMed search formula
due to keywords related to “exposure”, three were not
recognised due to keywords related to “study types”, and
six were not recognised due to both. For “exposure”terms, 26 articles could be identified by the addition of
the search term “fatty”. The remaining two articles related
to the term “exposure” reported fatty acid compositions
of tissues only. In the case of “study type” terms, none of
the nine articles used a general study design word (i.e.,
cohort, case-control, or cross-sectional), although the
STROBE statement recommends that authors should in-
dicate the study design with a commonly used term in
the title or abstract. These reporting characteristics made
it difficult to effectively search for observational studies
with a focus on individual fatty acids such as ARA. We
therefore adopted the search strategy described above.
The findings from articles for colorectal cancer differ
depending on the methodology of ARA exposure assess-
ment. A positive dose-response relationship between
dietary ARA intake and colorectal cancer was indicated
Table 3 Summary of observational studies on the association between ARA and risk of breast cancer
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Table 3 Summary of observational studies on the association between ARA and risk of breast cancer (Continued)
Study design: case-control study (temporal relationship among exposure and outcome is unclear)
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Table 3 Summary of observational studies on the association between ARA and risk of breast cancer (Continued)













































































































































































Table 3 Summary of observational studies on the association between ARA and risk of breast cancer (Continued)
Study design: cross-sectional study
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ARA Arachidonic acid, BMI Body mass index, DR Diet record, FD Food record, FFQ Food frequency questionnaire, GC Gas chromatography, HRT Hormone replacement therapy, MONICA multinational study for
Monitoring of Trends and Cardiovascular Disease study, MSP Mammary-Screening Project, NHS Nurses' Health study, NLCS Netherlands Cohort Study on Diet and Cancer, NYUWHS New York University Women's Health
Study, OR Odds ratio, ORDET study: the Hormones and Diet in the Etiology of Breast Cancer Risk study, PC Phosphatidyl-choline, PI Phosphatidyl-inositol, RR Relative risk, UK United Kingdom, USA United States of
America, VIP Västerbotten Intervention Project, WHR Waist-to-hip ratio, WR Weighed dietary record.
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http://www.biomedcentral.com/1471-2407/12/606in two reports [30,31], whereas four articles
[38,40,43,46] indicated a negative association or signifi-
cant ARA decrease with blood ARA levels, and no art-
icle reported a positive relationship between colorectal
cancer risk and tissue ARA level. These inconsistent
results seem to indicate that there is little firm evidence
that ARA correlates with the risk of cancer.
There were limited numbers of studies on skin cancer,
and they varied in the assessment method used for ARA
exposure and the target cancer. It is therefore impossible
to draw any conclusions from the results.
Among studies for breast and prostate cancer, a strong
positive association and a clear dose-response relation-
ship between increased cancer risk and ARA exposure
were not observed, although the results were replicated
in different settings using different methods. This sug-
gests that ARA exposure is not associated with increased
breast and prostate cancer risk.
We suppose that the contradictory findings mentioned
above were caused by four main factors. First, method-
ologies for estimating dietary ARA intake have not been
developed sufficiently. Most adults with mixed diets
consume approximately 50 to 250 mg of ARA per day
from foodstuffs [82-84], whereas some articles on colo-
rectal and prostate cancer have reported lower values
[30,36,39,68,74]. Various validated questionnaires were
used in articles which assessed dietary ARA intake, but
the validation was not conducted for ARA specifically;
total fat, saturated fatty acids, monounsaturated fatty
acids, polyunsaturated fatty acids, linoleic acid, or ei-
cosapentaenoic acid intake was assessed, but ARA was
not. Since the validity of the estimation of dietary ARA
intake is sometimes not enough [82], it should be con-
sidered whether exposure assessment is conducted with
an appropriate method.
Second, assessment of ARA biomarkers such as blood or
tissue ARA levels was diverse; assessed blood fractions
included erythrocyte, serum, plasma, or total blood. Tissue
sampling was conducted from adipose tissue of buttock or
malignant target cancer tissue (i.e., colon, skin, breast, and
prostate). Individual biomarkers of fatty acids represent
intakes for different time periods [85]. Serum or plasma
levels of ARA are considered to reflect dietary intake over a
few days, whereas erythrocyte and tissue ARA composition
serve as more long-term biomarkers. Overall, habitual diet-
ary ARA intake could not be assessed sufficiently in articles
that measured ARA composition of serum or plasma, and
this might be one of the causes of inconsistent results
among eligible articles.
Third, methodologies of participant selection used in the
reports could lead to selection bias. A nested case-control
study from a physicians’ health study (aspirin and beta-
carotene intervention study) did not consider trial interven-
tion through the participant selection procedure [73]. Also,reporting of participant selection was important; among the
total of 52 articles, 28 did not sufficiently report the eligibil-
ity criteria, and the sources and methods of participant se-
lection, and 31 did not fully describe the numbers of
individuals at each stage of the study and reasons for non-
participation. This makes it difficult to estimate the effect
of selection bias, and therefore, the relationship between
ARA intake and cancer risk could not be determined.
Fourth, publication bias based on findings of a significant
association could exist, especially in breast and prostate
cancers. We evaluated publication bias qualitatively, not
using any statistical tests. Most of the significant results
were found in the studies with low reporting quality. There
is a possibility of publication bias. The results of the studies
with low reporting quality may tend to be significant by
chance, due to the lack of appropriate design. This suggests
that publication bias may affect our review result on breast
and prostate cancers, but the effect should be small, be-
cause we did not give importance to these studies with low
reporting quality.
The biological plausibility of the relationship between
ARA intake and cancer risk is still being debated. Pre-
vious clinical studies with aspirin or nonsteroidal anti-
inflammatory drugs (NSAIDs) have suggested that the
cyclooxygenase metabolites of ARA may be associated with
risk for colorectal, breast, and prostate cancers [21-24].
Many observational studies, however, have failed to find
any association between ARA intake, or its level in blood
or tissue, and cancer risk. These controversial findings may
be explained by the following three reasons. First, ARA
levels of blood or tissue may not always represent dietary
intake. Garland et al. and Kobayashi et al. reported that cor-
relations between dietary estimates and the ARA contents
of adipose tissue or serum phospholipids were very low
[82,86]. Second, the increment of blood or tissue ARA
levels may not be connected with the amount of ARA
metabolites. Our previous study, in which the supplementa-
tion of 240 or 720 mg of ARA per day in healthy elderly
persons for four weeks was conducted, investigated plasma
PGE2 and urinary PGE2 metabolites [87]. Their concentra-
tions did not differ significantly with regard to ARA sup-
plementation or time points, although plasma ARA
compositions increased dose-dependently. Third, ARA
metabolites that are produced by pathways other than the
cyclooxygenase pathway may decrease cancer risk. LXA4
is an anti-inflammatory mediator produced by the lipoxy-
genase pathway and is regarded to be a suppressor of
tumour growth based on anti-angiogenic properties [25,88].
Aspirin or NSAIDs may not only inhibit the production of
cyclooxygenase metabolites, but also divert ARA into the
lipoxygenase pathway. However, it is unclear whether LXA4
contributes to reduced cancer risk in humans.
In the present study, we reviewed all bibliographies of
full-text articles for potential inclusion because reference
Table 4 Summary of observational studies on the association between ARA and risk of prostate cancer
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Table 4 Summary of observational studies on the association between ARA and risk of prostate cancer (Continued)
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http://www.biomedcentral.com/1471-2407/12/606searches serve an important role in comprehensive lit-
erature searches. 49,670 articles were listed, and 99.9%
of them were not eligible. We considered that this large
exclusion resulted from the many articles in which ARA
was not described at all; therefore, we tried another
reference search from the bibliographies of articles after
their exclusion. Fifty full-text articles from the PubMed
database and 146 from the reference search mentioned
ARA. A total of 13,657 articles were listed in their bibli-
ographies and their number was reduced to a third;
however, we could select 30 eligible articles out of 31
articles that were selected from all full-text searching.
The one article remaining that was not selected was a
report on skin cancer [50]. This might have resulted
from the smaller number of articles identified on
PubMed for skin cancer (10 reports) than for colorectal,
breast, or prostate cancers (48, 31, or 41 reports). This
suggests that reference searches from bibliographies of
articles including ARA are more efficient when enough
articles are identified from the PubMed database.
This systematic review has limitations. First, studies for
inclusion could not be selected independently by two or
more reviewers. Our inclusion/exclusion criteria were clear
and there were few differences which depended on who
was in charge; however that may have introduced a poten-
tial selection bias. Second, our search was restricted to Eng-
lish publications and articles from the PubMed database.
Furthermore, articles that investigated tissue levels of ARA
as an exposure assessment could not be identified compre-
hensively. We did not set the search terms for ARA levels
of tissue before the PubMed search, and identified the arti-
cles in the reference search. Third, the search term “fatty”
or “fatty acid” was not used in the PubMed search. It led to
the efficient search but may cause the possibility that the
review may not be completed. Fourth, quality assessment
of observational studies is difficult because of the hetero-
geneity of study designs and methods. The reporting quality
was quantitatively expressible using the STROBE checklist;
in contrast, the methodological quality could not be quanti-
fied and was qualitatively estimated by two independent
reviewers. This may have seriously influenced the results
and conclusions of the present review.
Note that there are insufficient studies to draw any firm
conclusions about the relationship between ARA and can-
cer risk. Further evidence from well-designed observational
studies is required.
Conclusions
In conclusion, we systematically identified articles that
investigated the association between dietary ARA intake
or its biomarkers and the risk of colorectal, skin, breast,
prostate, lung, or stomach cancer, and only a limited
number of observational studies were found (17, 3, 18,
16, 0, and 0 studies were found on colorectal, skin,breast, prostate, lung, or stomach cancer, respectively).
Furthermore, most studies had one or more critical lim-
itations, such as the obscurity of temporal information
about exposure and outcome, the methodology of ARA
exposure assessment, and inadequate treatment of po-
tential confounding factors. These studies did not suffi-
ciently demonstrate any relationships between ARA
exposure and cancer risk; however, they seem to suggest
that ARA exposure was not related to increased breast or
prostate cancer risk because strong positive associations
and clear dose-response relationships were not observed.
Findings concerning the association between ARA expos-
ure and colorectal cancer were inconsistent between
studies. Thus, further evidence from well-designed obser-
vational studies is required to confirm or refute the asso-
ciation between ARA exposure and cancer risk.
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